FDA approves new drug for chronic lymphocytic leukemia in patients with a specific chromosomal abnormality

The U.S. Food and Drug Administration approved Venclexta (venetoclax) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with at least one prior therapy. Venclexta is the first FDA-approved treatment that targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with CLL.

Related press announcement can be read at
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm495253.htm

THE OFFICIAL JOURNAL OF ISH

UPCOMING EVENTS

Sarıkadı Sok. No :22, Hamamonu Ankara/ Turkey
Phone : +90 532 580 38 76
E-Mail : ishinfo15@gmail.com

LookUs & Online Makale